These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 8158898

  • 1. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
    Kasiske BL, O'Donnell MP, Kim Y, Atluru D, Keane WF.
    Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
    [Abstract] [Full Text] [Related]

  • 2. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
    Guijarro C, Keane WF.
    Miner Electrolyte Metab; 1996 Feb; 22(1-3):147-52. PubMed ID: 8676808
    [Abstract] [Full Text] [Related]

  • 3. Lipids and progressive renal failure.
    Keane WF.
    Wien Klin Wochenschr; 1996 Feb; 108(14):420-4. PubMed ID: 8784983
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR, Pula KK, Alton KB, Burrier RE, Watkins RW.
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Inhibitors of HMG CoA reductase: new modes of action, new indications?].
    Essig M, Vrtovsnik F, Friedlander G.
    Therapie; 2000 Oct; 55(1):43-9. PubMed ID: 10860000
    [Abstract] [Full Text] [Related]

  • 10. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
    Hughes AD.
    J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
    [Abstract] [Full Text] [Related]

  • 11. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB, Silverman KC, Jayasuriya H, Kim BM, Amo SE, Wilson FR, Rew DJ, Schaber MD, Bergstrom JD, Koblan KS, Graham SL, Kohl NE, Gibbs JB, Singh SB.
    J Med Chem; 1998 Nov 05; 41(23):4492-501. PubMed ID: 9804689
    [Abstract] [Full Text] [Related]

  • 12. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase.
    Singh DK, Li L, Porter TD.
    J Pharmacol Exp Ther; 2006 Sep 05; 318(3):1020-6. PubMed ID: 16714400
    [Abstract] [Full Text] [Related]

  • 13. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS, Bacon SP, Illingworth DR.
    J Lab Clin Med; 2003 Apr 05; 141(4):250-6. PubMed ID: 12677170
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Structural mechanism for statin inhibition of HMG-CoA reductase.
    Istvan ES, Deisenhofer J.
    Science; 2001 May 11; 292(5519):1160-4. PubMed ID: 11349148
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH, Seeger JD.
    Pharmacotherapy; 1997 May 11; 17(6):1157-77. PubMed ID: 9399600
    [Abstract] [Full Text] [Related]

  • 20. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
    Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ.
    Clin Cancer Res; 2001 Jan 11; 7(1):158-67. PubMed ID: 11205904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.